VERDICT分析避免多参数前列腺MRI后不必要的活检:INNOVATE研究
INNOVATE研究在前列腺癌疑似男性中评估VERDICT MRI、ADC和PSAD对临床显著前列腺癌的诊断性能,发现病灶细胞内体积分数(FIC)的AUC为0.96,高于ADC(0.85)和PSAD(0.74),能更好分类临床显著前列腺癌。
要点
- 病灶FIC在Likert 3和4中均能区分临床显著前列腺癌。
- ADC仅对Likert 4有差异,PSAD对两者均无差异。
- FIC诊断临床显著前列腺癌的AUC高于ADC和PSAD。
关键影像表现/征象
- 临床显著前列腺癌病灶FIC中位数高于非临床显著病灶,Likert 3为0.53 vs 0.18(P=.002),Likert 4为0.60 vs 0.28(P<.001)。
- Likert 4病灶中,临床显著前列腺癌的ADC中位数低于非临床显著病灶(0.86×10-3 mm2/sec vs 1.12×10-3 mm2/sec,P=.03)。
- Likert 3病灶中ADC差异无统计学意义(0.97×10-3 mm2/sec vs 1.20×10-3 mm2/sec,P=.09)。
- PSAD在Likert 3(0.17 ng/mL2 vs 0.12 ng/mL2,P=.07)和Likert 4(0.14 ng/mL2 vs 0.12 ng/mL2,P=.47)中均无差异。
诊断标准与关键数值
- FIC诊断临床显著前列腺癌的AUC为0.96(95%CI:0.93,1.00)。
- ADC的AUC为0.85(95%CI:0.79,0.91),低于FIC(P=.02)。
- PSAD的AUC为0.74(95%CI:0.66,0.82),低于FIC(P=.02)。
临床应用与阅片要点
- 对mpMRI阳性(Likert≥3)病灶,可参考FIC值辅助判断临床显著前列腺癌,减少不必要活检。
- ADC在Likert 3病灶中鉴别价值有限,PSAD在Likert 3和4中均无显著差异。
局限性
- 仅165例活检初治男性纳入分析,样本量有限。
- 研究为前瞻性但仅一中心行VERDICT MRI,外部推广需验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background In men suspected of having prostate cancer (PCa), up to 50% of men with positive multiparametric MRI (mpMRI) findings (Prostate Imaging Reporting and Data System [PI-RADS] or Likert score of 3 or higher) have no clinically significant (Gleason score ≤3+3, benign) biopsy findings. Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumor (VERDICT) MRI analysis could improve the stratification of positive mpMRI findings. Purpose To evaluate VERDICT MRI, mpMRI-derived apparent diffusion coefficient (ADC), and prostate-specific antigen density (PSAD) as determinants of clinically significant PCa (csPCa). Materials and Methods Between April 2016 and December 2019, men suspected of having PCa were prospectively recruited from two centers and underwent VERDICT MRI and mpMRI at one center before undergoing targeted biopsy. Biopsied lesion ADC, lesion-derived fractional intracellular volume (FIC), and PSAD were compared between men with csPCa and those without csPCa, using nonparametric tests subdivided by Likert scores. Area under the receiver operating characteristic curve (AUC) was calculated to test diagnostic performance. Results Among 303 biopsy-naive men, 165 study participants (mean age, 65 years ± 7 [SD]) underwent targeted biopsy; of these, 73 had csPCa. Median lesion FIC was higher in men with csPCa (FIC, 0.53) than in those without csPCa (FIC, 0.18) for Likert 3 (P = .002) and Likert 4 (0.60 vs 0.28, P < .001) lesions. Median lesion ADC was lower for Likert 4 lesions with csPCa (0.86 × 10-3 mm2/sec) compared with lesions without csPCa (1.12 × 10-3 mm2/sec, P = .03), but there was no evidence of a difference for Likert 3 lesions (0.97 × 10-3 mm2/sec vs 1.20 × 10-3 mm2/sec, P = .09). PSAD also showed no difference for Likert 3 (0.17 ng/mL2 vs 0.12 ng/mL2, P = .07) or Likert 4 (0.14 ng/mL2 vs 0.12 ng/mL2, P = .47) lesions. The diagnostic performance of FIC (AUC, 0.96; 95% CI: 0.93, 1.00) was higher (P = .02) than that of ADC (AUC, 0.85; 95% CI: 0.79, 0.91) and PSAD (AUC, 0.74; 95% CI: 0.66, 0.82) for the presence of csPCa in biopsied lesions. Conclusion Lesion fractional intracellular volume enabled better classification of clinically significant prostate cancer than did apparent diffusion coefficient and prostate-specific antigen density. Clinical trial registration no. NCT02689271 © RSNA, 2022 Online supplemental material is available for this article.
引用
- Singh, Rogers, Kanber, et al. Avoiding Unnecessary Biopsy after Multiparametric Prostate MRI with VERDICT Analysis: The INNOVATE Study. Radiology. 2022. PMID: 35916679. doi:10.1148/radiol.212536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。